Saturday, February 27, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

USAMRIID’s Small-Molecule Antiviral Shows Efficacy Against Ebola

by Global Biodefense Staff
March 7, 2016
Ebola Outbreak Research and Analysis

Researchers at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have demonstrated that their novel small-molecule antiviral drug completely protected rhesus monkeys from Ebola virus when treated three days after infection.

The compound, known as GS-5734, blocks the virus’s ability to replicate its own genetic material, prohibiting it from making copies of itself.

The research findings were published last week in the journal Nature.

USAMRIID, Gilead Sciences, CDC Collaboration

Travis Warren, Ph.D., a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and first author of the paper, said the work is the result of continuing collaborations between USAMRIID and Gilead Sciences of Foster City, Calif.

Scientists at the Centers for Disease Control and Prevention (CDC) also contributed by performing initial screening of the Gilead Sciences compound library to find molecules with promising antiviral activity.

That initial work identified the precursor to GS-5734, a small-molecule antiviral agent, which led to the effort by Gilead and USAMRIID to further refine, develop and profile the compound. Led by USAMRIID Science Director Sina Bavari, Ph.D., the paper’s senior author, the research team used cell culture and animal models to demonstrate the compound’s antiviral activity against several pathogens, including Ebola virus.

See also: Rapid Medical Countermeasure Response to Infectious Diseases

In animal studies, treatment initiated on day 3 post-infection with Ebola virus resulted in 100 percent survival of the monkeys. The animals also exhibited a substantial reduction in viral load and a marked decrease in the physical signs of disease.

In cell culture studies, led at USAMRIID by Veronica Soloveva, Ph.D., GS-5734 was active against a broad spectrum of viral pathogens. These included Middle East Respiratory Syndrome (MERS) virus, Marburg virus, and multiple variants of Ebola virus, including the Makona strain causing the most recent outbreak in Western Africa.

“GS-5734 has several favorable characteristics for potential treatment of Ebola virus disease in humans. It is made using well-controlled chemical synthesis procedures, is stable, and can be made on a large scale,” Bavari commented. “It shows substantive post-exposure protection against Ebola virus in nonhuman primates, even when treatments were started after virus had spread to the blood in some animals.”

In addition, the researchers saw no evidence from genetic sequence analyses that the Ebola virus was able to generate resistance to GS-5734.

A Push for Further Development

Taken together, the robust therapeutic efficacy observed in primates, the favorable drug-like properties, and the potential for broad-spectrum antiviral activity suggest that further development of GS-5734 for the treatment of Ebola virus and other viral infections is warranted, Bavari said.

According to Tomas Cihlar, Ph.D., of Gilead Sciences, the company is currently conducting a series of phase I clinical studies in healthy human volunteers to establish the safety and pharmacokinetic profile of GS-5734.

See also: ZMapp Trial Shows Signs of Efficacy, But Data Insufficient

The compound also has been provided for compassionate use to treat two patients with Ebola virus infection, both of whom were discharged from the hospital. One of them was the Scottish nurse with recrudescent disease and the other was an acutely infected newborn, thus far the last identified case of Ebola virus infection in Guinea.

“With the hope that the West African outbreak will remain under control, we are exploring alternative options for the development path of GS-5734, including potential use of the animal efficacy rule,” Cihlar said. The animal rule is a regulatory mechanism under which the U.S. Food and Drug Administration may consider efficacy findings from adequate and well-controlled animal studies of a drug in cases where it is not feasible or ethical to conduct human trials.

Research on Ebola virus is conducted in Biosafety Level 4 (maximum containment) laboratories, where investigators wear positive-pressure “space suits” and breathe filtered air as they work. USAMRIID is the only organization in the Department of Defense with Biosafety Level 4 capabilities, and its research benefits both military personnel and civilians.

Read more at Nature: Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.

Tags: Animal ModelsAntiviralsBiosafetyEbolaEmerging Threats

Related Posts

Sign on street in Conakry that says Ebola in large letters
Biosecurity

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
Thin Film Freezing Shows Efficacy for Biodefense Countermeasures Against Alphaviruses and Filoviruses
Industry News

Thin Film Freezing Shows Efficacy for Biodefense Countermeasures Against Alphaviruses and Filoviruses

February 19, 2021
Ebola Strikes West Africa Again: Key Questions and Lessons from the Past
Biosurveillance

Ebola Strikes West Africa Again: Key Questions and Lessons from the Past

February 18, 2021
One Drug to Defeat All Filoviruses?
Medical Countermeasures

One Drug to Defeat All Filoviruses?

February 14, 2021
Load More

Latest News

First Human Trial of COVID-19 Vaccine Finds it is Safe and Induces Rapid Immune Response

COVID-19 Vaccination: What We Can Learn From the Great Polio Vaccine Heist of 1959

February 24, 2021
Sign on street in Conakry that says Ebola in large letters

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
How Roald Dahl Became a Passionate Vaccine Advocate

How Roald Dahl Became a Passionate Vaccine Advocate

February 23, 2021
How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

February 23, 2021

Upcoming Events

Mar 1
Virtual Event
All day

Rare Disease Day at NIH 2021 – Virtual Conference

Mar 2
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 2
Virtual Event
4:00 pm - 6:00 pm

RNA Viruses: How They Do What They Do

Mar 2
Virtual Event
5:00 pm - 7:00 pm

COVID Seminar Series – Hindsight is 2020

Mar 4
Virtual Event
10:00 am - 1:30 pm

Vulnerabilities in U.S. Chemical Weapons Detection, Identification, and Tracing

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC